School of Postgraduate Studies, Development and Innovation, International Medical University, Kuala Lumpur, Malaysia.
School of Health Sciences, and Development and Innovation, International Medical University, Kuala Lumpur, Malaysia.
Microb Drug Resist. 2021 Feb;27(2):234-240. doi: 10.1089/mdr.2020.0178. Epub 2020 Jun 23.
Currently, limited antibiotics are available to treat methicillin-resistant (MRSA) infections. One approach is the use of adjuvants in antibiotic therapy. 1,4-Naphthoquinones are naturally occurring alkaloids shown to have antibacterial properties. The objective of this study is to investigate the synergy between 1,4-naphthoquinone and selected β-lactam antibiotics and to evaluate the potential use of 1,4-naphthoquinone as an adjuvant in antibiotic treatment against MRSA infections. The antibacterial activity of 1,4-naphthoquinone and plumbagin was tested against nine pathogenic bacterial strains using the microdilution broth method. The interactions between 1,4-naphthoquinone and three antibiotics (cefuroxime, cefotaxime, and imipenem) were estimated by calculating the fractional inhibitory concentration of the combination. The compounds 1,4-naphthoquinone and plumbagin exhibited a broad range of bacteriostatic and bactericidal effects against both Gram-positive and Gram-negative bacteria. The interaction between 1,4-naphthoquinone and imipenem, cefuroxime, and cefotaxime was synergistic against methicillin-sensitive and MRSA clinical strains. Against ATCC-cultured MRSA, a synergistic effect was observed between 1,4-naphthoquinone and cefotaxime. However, combination with imipenem only produced an additive effect, and an antagonistic action was observed between 1,4-naphthoquinone and cefuroxime. Although individually less potent than common antibiotics, 1,4-naphthoquinone acts synergistically with imipenem, cefuroxime, and cefotaxime against MRSA clinical strains and could potentially be used in adjuvant-antibiotic therapy against multidrug resistant bacteria.
目前,治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的抗生素有限。一种方法是在抗生素治疗中使用佐剂。1,4-萘醌是一种具有抗菌特性的天然存在的生物碱。本研究旨在探讨 1,4-萘醌与选定的β-内酰胺类抗生素之间的协同作用,并评估 1,4-萘醌作为治疗 MRSA 感染的抗生素佐剂的潜在用途。采用微量稀释肉汤法检测 1,4-萘醌和白花丹醌对 9 株致病性细菌的抗菌活性。通过计算组合的部分抑菌浓度来评估 1,4-萘醌与三种抗生素(头孢呋辛、头孢噻肟和亚胺培南)之间的相互作用。化合物 1,4-萘醌和白花丹醌对革兰氏阳性菌和革兰氏阴性菌均表现出广泛的抑菌和杀菌作用。1,4-萘醌与亚胺培南、头孢呋辛和头孢噻肟之间的相互作用对甲氧西林敏感和 MRSA 临床株均具有协同作用。对 ATCC 培养的 MRSA,1,4-萘醌与头孢噻肟之间观察到协同作用。然而,与亚胺培南联合仅产生相加作用,1,4-萘醌与头孢呋辛之间观察到拮抗作用。尽管单独使用比常用抗生素的效力低,但 1,4-萘醌与亚胺培南、头孢呋辛和头孢噻肟对 MRSA 临床株具有协同作用,可能在针对多药耐药菌的辅助抗生素治疗中使用。